1 min read
Munich Court Overturns Injunction Against Merck in Keytruda Patent Dispute
The dispute involves Halozyme and Merck over Merck’s injectable version of Keytruda.

Halozyme shares fell Thursday after a Munich court overturned a preliminary injunction against Merck in a patent dispute over Merck’s injectable version of Keytruda.
The injunction was issued last year. The patent dispute involves Halozyme and Merck over Merck’s injectable version of Keytruda.